BioSpace News Archive

Anesthesia masks are rubber or silicone masks that cover both the mouth and the nose of a patient to supply proper anesthetic reagents inside the body that makes and keeps a person completely unconscious during an operation

Curettes the efficient removal of superficial malignant tumors and benign skin neoplasms ensuring minimal damage to the surrounding tissue.

a structure in cells that breaks down substances, such as proteins, carbohydrates, and old cell parts so the body can recycle them.

Thousands of deaths are occurring on a yearly basis on account of various viral infectious diseases. Some of the viral diseases occurring are rabies, avian influenza, HIV-1, measles, enterovirus, poliovirus, coronavirus, and Metapneumovirus.

Net sales amounted to 298.1 MSEK (288.6), an increase by 3.3 percent, and organically* an increase by 10.0 percent.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that the European Commission has approved Ogluo™ injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, will publish its year-end report for 2020 on February 26, 2021, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.

Data Include Positive Safety and Tolerability Profile, and Preliminary Efficacy Results for Boosted Oral Formulation of Docetaxel

Mallinckrodt plc , a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is deferring action (pending a site inspection) on the Stratatech Biologics License Application (BLA) for StrataGraft ® , an investigational allogeneic cellularized scaffold product

European Commission Approves Seagen’s TUKYSA ® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer - Approved for Adult Patients with HER2-Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Anti-HER2 Treatment Regimens -